- Age and gender peculiarities of lipid profile in children and adolescents with cholelithiasis
Age and gender peculiarities of lipid profile in children and adolescents with cholelithiasis
PERINATOLOGY AND PEDIATRIC. UKRAINE. 2017.3(71):115-119; doi 10.15574/PP.2017.71.115
Shutova O. V.
Kharkiv Medical Academy of Postgraduate Education, Ukraine
Purpose — to study the features of the lipid profile in children and adolescents with cholelithiasis, taking into account gender and age.
Patients and methods. Under supervision were 79 children (44 girls and 35 boys) 4–17 years with cholelithiasis (CSF). For the interpretation of the data obtained, groups were assigned according to age: 4–8 years, 10–13 years, 14–17 years. Qualitative assessment of lipid profile in children and adolescents was carried out in accordance with the adapted criteria of NCEP / ATP III and IDF. At statistical processing the licensed software products (Statistica, Excel) are used.
Results. In boys 4–7 years, the level of OXC, HDL cholesterol and LDL cholesterol was significantly higher than that of female girls (p <0.05). In the group of adolescents aged 10–13 years, the highest values of HDL cholesterol and cholesterol-lowering cholesterol were determined in girls (p<0.05), and the values of atherogenicity coefficient, in contrast, in boys (p<0.05). Multidirectional correlations of the patient's age with HDL cholesterol were found (in boys: r=-0.83, p<0.001, in girls: r=0.98, p<0.01) and LDL cholesterol (in boys: r=-0.72; p<0.001, in girls: r=0.58, p<0.01).
Conclusions. In children with CSF, the characteristics of the lipid spectrum are determined by sex, age and duration of the disease. The greatest deviations in lipid metabolism are characteristic for boys 4–7 years and girls 14–17 years. The peculiarity of dyslipoproteinemia in patients with GAD is an increase in the level of OXC and HDL cholesterol on the background of increased LDL cholesterol production and a decrease in VLDL cholesterol.
Key words: cholelithiasis, diagnosis, lipid profile, sex, age, children.
1. Skvorcova THe, Sitkin SI, Radchenko VG, Seliverstov PV, Tkachenko EI. (2013). Gallstone diseases. Modern approaches to diagnosis, treatment and prevention. Moscow, Forte print: 32.
2. Zaprudnov AM. (2008). Biliary pathology in children. Moscow: 376.
3. Tyuryumin YaL, Shanturov VA, Tyuryumina EE. (2012). Physiology of cholesterol metabolism (the review). Bulletin of the East Siberian Scientific Center SBRAMS. 84(2); Pt 1: 153–158.
4. Unified clinical protocols of medical care for children with diseases of the digestive system the order N 59 2013 Jan 29. Kiev: The Ministry of Health Ukraine. http://www.moz.gov.ua/docfiles/dod59_2_2013.pdf.
5. Shadrin OG, Shutova OV. (2015). Evaluation of indicators of АPO-АI, АPO-В, АPO-Е apolipoproteins and their correlation with phenotype АPO-Е in children with cholelithiasis. East European Scientific Journal. 4(1): 149−153.
6. Shutova EV, Belousova OYu, Pavlenko NV. (2015). Optimization of diagnosis of early stage of gallstone disease in children. Sovremennaya pediatriya. 2(36): 88–91. doi 10.15574/SP.2015.65.88
7. Shutova EV. (2014). Clinical features and biocamical markers of cholesterol cholelitiasis among children. Perinatologiya i pediatriya. 58(2): 119–123. doi 10.15574/PP.2014.58.119.
8. Shutova EV. (2016). Apolipoprotein E polymorphism and lipid metabolism disorders in children with cholelithiasis. Child's health. 73 (5): 101–106.
9. Shcherbynyna MB. (2012). Gallstone disease: therapeutic aspects. Kyev, Medknyha: 223.
10. Espinosa-Saavedra D, Flores-Calderón J, González-Ortiz B, Rodríguez-González P. (2014). Characteristics of pediatric patients with biliary lithiasis. Immediate post-operative evolution. Rev Med Inst Mex Seguro Soc. 52; Suppl 2: S74–S77.
11. Nissinen MJ, Pakarinen MP, Gylling H, Koivusalo A. (2013). Cholesterol and non-cholesterol sterols in serum and gallstones interfere with pathogenesis of pediatric gallstone disease: poster presentations 1310. Hepatology. 58 Suppl 1: Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2013. November 1-2, 2013. Washington, D.C., USA: 844A.
12. Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. European Association for the Study of the Liver (EASL). (2016). J Hepatol. 65(1): 146–181. doi 10.1016/j.jhep.2016.03.005.
13. Jolliffe CJ, Janssen I. (2007). Development of age-specific adolescent metabolic syndrome criteria that are linked to the Adult Treatment Panel III and International Diabetes Federation criteria. J Am Coll Cardiol. 49(8): 891–898.
14. Stinton LM, Shaffer EA. (2012). Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. Gut and Liver. 6(2): 172–187. doi 10.5009/gnl.2012.6.2.172.
15. Svensson J, Makin E. (2012). Gallstone disease in children. Semin Pediatr Surg. 21(3): 255–265. doi 10.1053/j.sempedsurg.2012.05.008.